Anti-inflammatory therapeutics market size was $98,026 million in 2020 and is projected to reach $125,552 million by 2028, registering a CAGR of 4.0% from 2021 to 2028.
List of Key Players
The key market players profiled in the report include Pfizer, Inc., Abbvie, Inc., Johnson & Johnson, GlaxoSmithKline, Merck & CO., Inc., Novartis, F. Hoffman, La Roche AG, Eli Lily and Company, AstraZeneca PLC, and Amgen.
Download Sample Report: https://www.alliedmarketresearch.com/request-sample/286
The key factors driving the growth of the global anti-inflammatory market include alarming increase in prevalence of autoimmune & respiratory conditions, new drugs in pipeline, and surge adoption of anti-inflammatory drugs. Furthermore, the demand for anti-inflammatory drugs has been increasing notably, owing to the emergence of anti-inflammatory biologics that are more targeted, effective, and with lesser side effects as compared to conventional drugs. Moreover, rise in awareness of anti-inflammatory therapeutics and attractive government initiatives toward the use of nonsteroidal anti-inflammatory drugs in the Asia-Pacific and LAMEA are expected to augment the market growth during the analysis period. However, side effects of anti-inflammatory drugs and patent expiry issues of blockbuster drugs (such as Remicade) are known to impede the anti-inflammatory therapeutics market growth.
For Purchase inquiry: https://www.alliedmarketresearch.com/purchase-enquiry/286
The global anti-inflammatory therapeutics market is segmented into indication, drug class, and region. On the basis of indication, the market is categorized into arthritis, respiratory diseases, multiple sclerosis, psoriasis, anti-inflammatory bowel disease (IBD), and other anti-inflammatory diseases. Arthritis is expected to register the highest CAGR during the forecast period, owing to increase in geriatric population, as it is found to be more prevalent in the geriatric population and cause inflammation in joints.
Depending on drug class, it is fragmented into nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and biologics. The nonsteroidal anti-inflammatory drugs (NSAIDs) is expected to register the highest CAGR during the forecast period, owing to increase in patient population suffering from chronic disease and unavailability of effective treatments. Moreover, increase in affordability coupled with high healthcare spending and rise in awareness of biologics, especially, in emerging markets are expected to represent a huge market potential for biologics. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
North America accounted for the largest market share in 2020, and is anticipated to maintain its dominance from 2020 to 2028, due to high expenditure on R&D, presence of major players & their product availability, and well-established healthcare infrastructure in the region. However, Asia-Pacific is expected to register the highest CAGR during the forecast period, as governments of Asian countries are investing in the development of healthcare infrastructure.
Medical Imaging Reagents Market
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP, based in Portland, Oregon. AMR provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.